Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma.

Hensel J, Wetterwald A, Temanni R, Keller I, Riether C, van der Pluijm G, Cecchini MG, Thalmann GN.

Oncotarget. 2018 Jun 22;9(48):28877-28896. doi: 10.18632/oncotarget.25608. eCollection 2018 Jun 22.

2.

Transplantable Animal Studies and Whole-Body Optical Imaging in Prostate Carcinoma.

van der Horst G, van der Mark M, Cheung H, van der Pluijm G.

Methods Mol Biol. 2018;1786:81-102. doi: 10.1007/978-1-4939-7845-8_5.

PMID:
29786788
3.

Protocols for Migration and Invasion Studies in Prostate Cancer.

van de Merbel AF, van der Horst G, Buijs JT, van der Pluijm G.

Methods Mol Biol. 2018;1786:67-79. doi: 10.1007/978-1-4939-7845-8_4.

PMID:
29786787
4.

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]

PMID:
29696636
5.

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models.

Astrologo L, Zoni E, Karkampouna S, Gray PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm G, Spahn M, Thalmann GN, Ten Dijke P, Kruithof-de Julio M.

Front Cell Dev Biol. 2017 Dec 5;5:104. doi: 10.3389/fcell.2017.00104. eCollection 2017.

6.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

PMID:
29158269
7.

Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program.

Taurozzi AJ, Beekharry R, Wantoch M, Labarthe MC, Walker HF, Seed RI, Simms M, Rodrigues G, Bradford J, van der Horst G, van der Pluijm G, Collins AT.

PLoS One. 2017 Nov 16;12(11):e0188228. doi: 10.1371/journal.pone.0188228. eCollection 2017.

8.

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, Kelber J, Pelger RCM, Henry MD, Snaar-Jagalska E, van Leenders GJLH, Beimers L, Kloen P, Gray PC, van der Pluijm G, Kruithof-de Julio M.

Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.

9.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911. No abstract available.

10.

A zebrafish xenograft model for studying human cancer stem cells in distant metastasis and therapy response.

Chen L, Groenewoud A, Tulotta C, Zoni E, Kruithof-de Julio M, van der Horst G, van der Pluijm G, Ewa Snaar-Jagalska B.

Methods Cell Biol. 2017;138:471-496. doi: 10.1016/bs.mcb.2016.10.009. Epub 2016 Dec 9. Review.

PMID:
28129855
11.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: Biol Open. 2017 Feb 15;6(2):309.

12.

The role of microRNAs in bone metastasis.

Zoni E, van der Pluijm G.

J Bone Oncol. 2016 Jul 8;5(3):104-108. eCollection 2016 Sep.

13.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E.

Int J Mol Sci. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375.

14.

XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.

Semenchenko K, Wasylyk C, Cheung H, Tourrette Y, Maas P, Schalken JA, van der Pluijm G, Wasylyk B.

PLoS One. 2016 Jul 18;11(7):e0159531. doi: 10.1371/journal.pone.0159531. eCollection 2016.

15.

Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.

Kroon J, Kooijman S, Cho NJ, Storm G, van der Pluijm G.

Trends Pharmacol Sci. 2016 Jun;37(6):451-462. doi: 10.1016/j.tips.2016.03.003. Epub 2016 Apr 8. Review.

PMID:
27068431
16.

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G.

Endocr Relat Cancer. 2016 Jan;23(1):35-45. doi: 10.1530/ERC-15-0343. Epub 2015 Oct 19.

17.

miR-25, integrin and cancer invasiveness.

Zoni E, Kruithof-de Julio M, van der Pluijm G.

Oncoscience. 2015 Aug 24;2(8):663-4. eCollection 2015. No abstract available.

18.

Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-β-, Notch-, and Wnt-Mediated EMT.

Zoni E, van der Pluijm G, Gray PC, Kruithof-de Julio M.

J Oncol. 2015;2015:198967. doi: 10.1155/2015/198967. Epub 2015 Mar 25. Review.

19.

miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression.

Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, Pelger RC, Collins AT, Visakorpi T, Snaar-Jagalska BE, Maitland NJ, van der Pluijm G.

Cancer Res. 2015 Jun 1;75(11):2326-36. doi: 10.1158/0008-5472.CAN-14-2155. Epub 2015 Apr 9.

20.

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

Kroon J, Buijs JT, van der Horst G, Cheung H, van der Mark M, van Bloois L, Rizzo LY, Lammers T, Pelger RC, Storm G, van der Pluijm G, Metselaar JM.

Prostate. 2015 Jun;75(8):815-24. doi: 10.1002/pros.22963. Epub 2015 Feb 8.

21.

The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.

Özdemir BC, Hensel J, Secondini C, Wetterwald A, Schwaninger R, Fleischmann A, Raffelsberger W, Poch O, Delorenzi M, Temanni R, Mills IG, van der Pluijm G, Thalmann GN, Cecchini MG.

PLoS One. 2014 Dec 8;9(12):e114530. doi: 10.1371/journal.pone.0114530. eCollection 2014.

22.

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.

Buijs JT, Matula KM, Cheung H, Kruithof-de Julio M, van der Mark MH, Snoeks TJ, Cohen R, Corver WE, Mohammad KS, Jonkers J, Guise TA, van der Pluijm G.

J Pathol. 2015 Apr;235(5):745-59. doi: 10.1002/path.4488. Epub 2015 Jan 23.

23.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

24.

Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth.

Kroon J, in 't Veld LS, Buijs JT, Cheung H, van der Horst G, van der Pluijm G.

Oncotarget. 2014 Oct 15;5(19):8986-94.

25.

Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.

Wissing MD, De Morrée ES, Dezentjé VO, Buijs JT, De Krijger RR, Smit VT, Van Weerden WM, Gelderblom H, van der Pluijm G.

Oncotarget. 2014 Sep 15;5(17):7357-67.

26.

Targeting of alpha-v integrins reduces malignancy of bladder carcinoma.

van der Horst G, Bos L, van der Mark M, Cheung H, Heckmann B, Clément-Lacroix P, Lorenzon G, Pelger RC, Bevers RF, van der Pluijm G.

PLoS One. 2014 Sep 23;9(9):e108464. doi: 10.1371/journal.pone.0108464. eCollection 2014.

27.

Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187.

Reeves KJ, Hurrell JE, Cecchini M, van der Pluijm G, Down JM, Eaton CL, Hamdy F, Clement-Lacroix P, Brown NJ.

Int J Cancer. 2015 Apr 1;136(7):1731-40. doi: 10.1002/ijc.29165. Epub 2014 Sep 4.

28.

Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.

Bachelier R, Confavreux CB, Peyruchaud O, Croset M, Goehrig D, van der Pluijm G, Clézardin P.

Int J Cancer. 2014 Sep 15;135(6):1319-29. doi: 10.1002/ijc.28787. Epub 2014 Mar 3.

29.

Metastasis of prostate cancer and melanoma cells in a preclinical in vivo mouse model is enhanced by L-plastin expression and phosphorylation.

Riplinger SM, Wabnitz GH, Kirchgessner H, Jahraus B, Lasitschka F, Schulte B, van der Pluijm G, van der Horst G, Hämmerling GJ, Nakchbandi I, Samstag Y.

Mol Cancer. 2014 Jan 18;13:10. doi: 10.1186/1476-4598-13-10.

30.

Liposomal nanomedicines in the treatment of prostate cancer.

Kroon J, Metselaar JM, Storm G, van der Pluijm G.

Cancer Treat Rev. 2014 May;40(4):578-84. doi: 10.1016/j.ctrv.2013.10.005. Epub 2013 Oct 25. Review.

PMID:
24216226
31.

BMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality.

Boon MR, van den Berg SA, Wang Y, van den Bossche J, Karkampouna S, Bauwens M, De Saint-Hubert M, van der Horst G, Vukicevic S, de Winther MP, Havekes LM, Jukema JW, Tamsma JT, van der Pluijm G, van Dijk KW, Rensen PC.

PLoS One. 2013 Sep 16;8(9):e74083. doi: 10.1371/journal.pone.0074083. eCollection 2013.

32.

Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.

Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H.

Clin Cancer Res. 2013 Nov 1;19(21):5822-7. doi: 10.1158/1078-0432.CCR-13-1896. Epub 2013 Sep 19. Review.

33.

Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma.

van der Horst G, Bos L, van der Pluijm G.

Mol Cancer Res. 2012 Aug;10(8):995-1009. doi: 10.1158/1541-7786.MCR-12-0274. Epub 2012 Jun 19. Review.

34.

Preclinical imaging of the cellular and molecular events in the multistep process of bone metastasis.

van der Horst G, van der Pluijm G.

Future Oncol. 2012 Apr;8(4):415-30. doi: 10.2217/fon.12.33. Review.

PMID:
22515445
35.

Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.

Germann M, Wetterwald A, Guzmán-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED, Thalmann GN.

Stem Cells. 2012 Jun;30(6):1076-86. doi: 10.1002/stem.1087.

36.

Preclinical models that illuminate the bone metastasis cascade.

van der Horst G, van der Pluijm G.

Recent Results Cancer Res. 2012;192:1-31. doi: 10.1007/978-3-642-21892-7_1. Review.

PMID:
22307368
37.

The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation.

Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J, Petersen M, van Overveld PG, Pelger RC, van der Pluijm G.

Oncogene. 2012 Apr 26;31(17):2164-74. doi: 10.1038/onc.2011.400. Epub 2011 Sep 26.

PMID:
21996751
38.

BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β(3) expression.

Naber HP, Wiercinska E, Pardali E, van Laar T, Nirmala E, Sundqvist A, van Dam H, van der Horst G, van der Pluijm G, Heckmann B, Danen EH, Ten Dijke P.

Cell Oncol (Dordr). 2012 Feb;35(1):19-28. doi: 10.1007/s13402-011-0058-0. Epub 2011 Sep 21.

39.

Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency.

Boon MR, van der Horst G, van der Pluijm G, Tamsma JT, Smit JW, Rensen PC.

Cytokine Growth Factor Rev. 2011 Aug;22(4):221-9. doi: 10.1016/j.cytogfr.2011.08.001. Epub 2011 Sep 15. Review.

PMID:
21924665
40.

Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer.

van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G.

Am J Pathol. 2011 Nov;179(5):2559-68. doi: 10.1016/j.ajpath.2011.07.011. Epub 2011 Sep 9.

41.

Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.

Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P, Thalmann G.

Prostate. 2012 May 15;72(7):713-20. doi: 10.1002/pros.21473. Epub 2011 Aug 31.

PMID:
21882211
42.

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément-Lacroix P, van der Pluijm G.

Neoplasia. 2011 Jun;13(6):516-25.

43.

The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis.

van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G.

Clin Exp Metastasis. 2011 Oct;28(7):615-25. doi: 10.1007/s10585-011-9395-7. Epub 2011 Jun 7.

44.

Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis.

van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, Bevers RF, Pelger RC, van der Pluijm G.

Eur Urol. 2011 Aug;60(2):337-43. doi: 10.1016/j.eururo.2011.05.005. Epub 2011 May 19.

PMID:
21616583
45.

Breast cancer bone metastases: denosumab or zoledronic acid?

van der Pluijm G.

Nat Rev Endocrinol. 2011 Mar;7(3):134-5. doi: 10.1038/nrendo.2011.18. No abstract available.

PMID:
21343953
46.

The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.

Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P.

Breast Cancer Res Treat. 2011 Aug;128(3):657-66. doi: 10.1007/s10549-010-1147-x. Epub 2010 Sep 5.

PMID:
20821046
47.

Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.

Buijs JT, Kuijpers CC, van der Pluijm G.

Curr Pharm Des. 2010;16(27):3015-27. Review.

PMID:
20722621
48.

Epithelial plasticity, cancer stem cells and bone metastasis formation.

van der Pluijm G.

Bone. 2011 Jan;48(1):37-43. doi: 10.1016/j.bone.2010.07.023. Epub 2010 Jul 27. Review.

PMID:
20670698
49.

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.

van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RC, van der Pluijm G.

Cancer Res. 2010 Jun 15;70(12):5163-73. doi: 10.1158/0008-5472.CAN-09-3806. Epub 2010 Jun 1.

50.

Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?

Buijs JT, Petersen M, van der Horst G, van der Pluijm G.

Curr Pharm Des. 2010;16(11):1291-300. Review.

PMID:
20166979

Supplemental Content

Loading ...
Support Center